绝经泌尿生殖综合征现代治疗方式的比较疗效与安全性:系统评价与网络Meta分析
该系统评价与网络Meta分析比较了绝经泌尿生殖综合征(GSM)多种现代疗法的相对疗效与安全性,纳入24个随机对照试验家族共4958名受试者。主要症状网络Meta分析含15个试验家族、7个节点、3415名受试者,与安慰剂/假对照/对照相比,局部阴道雌激素是唯一置信区间不包含无效线的类别(SMD 0.34,95%CI 0.02–0.66)。
要点
- 局部阴道雌激素是唯一与对照相比置信区间不包含无效线的类别(SMD 0.34,95%CI 0.02–0.66)。
- 普拉睾酮、透明质酸、奥培米芬、保湿剂/润滑剂及CO2激光的估计值均不精确,置信区间包含无效线。
- 异质性仍具实质性(τ²=0.097;I²=65.6%),节点分割未检出局部不一致性(所有p≥0.35)。
核心结论
- 与安慰剂/假对照/对照相比,局部阴道雌激素是唯一置信区间不包含无效线的类别(SMD 0.34,95%CI 0.02–0.66)。
- 普拉睾酮(0.37,−0.10至0.84)、透明质酸(0.31,−0.10至0.72)、奥培米芬(0.24,−0.38至0.87)、保湿剂/润滑剂(0.15,−0.37至0.67)及CO2激光(0.03,−0.56至0.61)的估计值均不精确。
研究设计与样本
- 系统评价与类别水平网络Meta分析,检索MEDLINE/PubMed、Scopus、Cochrane CENTRAL、Web of Science、Google Scholar、ClinicalTrials.gov及WHO ICTRP,自建库至2026年3月,并进行前后向引文检索。
- 纳入绝经后伴有症状性GSM或等同诊断女性的随机对照试验,两名评价者独立筛选、提取并关联同一试验家族的报告,采用RoB 2评估偏倚风险。
- 主要结局为统一的患者报告症状负担,采用预设层级:整体症状评分、最困扰症状、性交痛及阴道干燥;采用频率学派随机效应一致性网络Meta分析。
- 26篇疗效出版物代表24个独特试验家族、经分母裁定后4958名随机受试者;主要症状网络Meta分析纳入15个试验家族、7个节点、3415名受试者。
主要发现
- 与安慰剂/假对照/对照相比,局部阴道雌激素SMD 0.34(95%CI 0.02–0.66),是唯一置信区间不包含无效线的类别。
- 普拉睾酮SMD 0.37(−0.10至0.84)、透明质酸SMD 0.31(−0.10至0.72)、奥培米芬SMD 0.24(−0.38至0.87)、保湿剂/润滑剂SMD 0.15(−0.37至0.67)、CO2激光SMD 0.03(−0.56至0.61),估计值均不精确。
- 异质性仍具实质性(τ²=0.097;I²=65.6%)。
- 节点分割未显示统计学可检出的局部不一致性(所有p≥0.35),全局设计-by-治疗交互分解亦不显著(Q=4.90,df原文未写明)。
- 采用经验证的百分比贡献矩阵,以CINeMA评估全部21项网络比较的置信度。
局限性
- 异质性仍具实质性(τ²=0.097;I²=65.6%)。
- 普拉睾酮、透明质酸、奥培米芬、保湿剂/润滑剂及CO2激光的估计值均不精确。
- 原文报告全局设计-by-治疗交互分解的Q=4.90,但df原文未写明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Background Genitourinary syndrome of menopause (GSM) is a chronic consequence of hypoestrogenism affecting vaginal, sexual and lower urinary tract health. Treatments include local vaginal oestrogen, intravaginal prasterone, oral ospemifene, hyaluronic acid preparations, moisturisers/lubricants and energy-based interventions, but comparative evidence is heterogeneous. Objectives To compare the relative efficacy and safety of contemporary GSM therapies using a systematic review and class-level network meta-analysis (NMA) of randomised controlled trials. Search Strategy MEDLINE/PubMed, Scopus, Cochrane CENTRAL, Web of Science, Google Scholar, ClinicalTrials.gov and WHO ICTRP were searched from inception to March 2026, with backward and forward citation searching. Selection Criteria Randomised controlled trials enrolling postmenopausal women with symptomatic GSM or equivalent diagnoses. Data Collection and Analysis Two reviewers independently screened, extracted and linked reports from the same trial family and assessed RoB 2. The primary outcome was harmonised patient-reported symptom burden, using a prespecified hierarchy of global symptom score, most bothersome symptom, dyspareunia and vaginal dryness. A frequentist random-effects consistency NMA generated; Hedges g standardised mean differences (SMDs), 95% confidence intervals (CIs), prediction intervals and P-scores. Heterogeneity was estimated by REML; node splitting, a design-by-treatment interaction decomposition and sensitivity analyses assessed incoherence and influence. Confidence in all 21 network comparisons was evaluated with CINeMA using a validated percentage contribution matrix. Results Twenty-six efficacy publications represented 24 unique trial families and 4958 randomised participants after denominator adjudication. The primary symptom NMA included 15 trial families, seven nodes and 3415 participants. Versus placebo/sham/control, local vaginal oestrogen was the only class with a CI excluding the null (SMD 0.34, 95% CI 0.02–0.66). Estimates were imprecise for prasterone (0.37, −0.10 to 0.84), hyaluronic acid (0.31, −0.10 to 0.72), ospemifene (0.24, −0.38 to 0.87), moisturiser/lubricant (0.15, −0.37 to 0.67) and CO2 laser (0.03, −0.56 to 0.61). Heterogeneity remained material (τ 2 = 0.097; I 2 = 65.6%). Node splitting showed no statistically detectable local incoherence (all p ≥ 0.35) and the global design-by-treatment interaction decomposition was also non-significant (Q = 4.90, df
引用
- BJOG:Comparative Efficacy and Safety of Modern Treatment Modalities for Genitourinary Syndrome of Menopause: A Systematic Review and Network Meta‐Analysis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。